| Identification | Back Directory | [Name]
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester | [CAS]
641569-97-3 | [Synonyms]
Nilotinib intermediate 2
Ethyl 4-methyl-3-((4-(pyridin-3-yl)
Ethyl 4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)benzoate
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester
Benzoic acid, 4-Methyl-3-[[4-(3-pyridinyl)-2-pyriMidinyl]aMino]-, ethyl ester | [Molecular Formula]
C19H18N4O2 | [MDL Number]
MFCD11100712 | [MOL File]
641569-97-3.mol | [Molecular Weight]
334.37 |
| Questions And Answer | Back Directory | [Uses]
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic Acid Ethyl Ester-D6 is an intermediate in the synthesis of Nilotinib-d6 (N465303), which is the labeled analogue of Nilotinib, which might be useful in treatment of chronic myelogenous leukemia. |
| Hazard Information | Back Directory | [Description]
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester is a pharmaceutical intermediate compound used in the preparation of nilotinib, a transactivation inhibitor targeting BCR-ABL, c-kit, and PDGF, which is used in the treatment of a variety of leukaemia, including chronic granulocytic leukaemia (CML). Chronic granulocytic leukaemia (CML) is caused by the BCR-ABL oncogene. Nilotinib inhibits the tyrosine kinase activity of the BCR-ABL protein. |
|
|